The Aspen Neuroscience IPO was priced at $15 per share, with the biotechnology company offering 9,375,000 shares and expecting approximately $140.6 million in gross proceeds. The shares are expected to begin trading on the Nasdaq Global Select Market on October 30, 2026, under the ticker ASPE.

Key Takeaways

  • Aspen is offering all shares in the IPO, with proceeds stated before underwriting costs and other expenses.
  • The offering is expected to close on November 2, 2026, subject to customary conditions.

Aspen Neuroscience IPO terms

Aspen announced the pricing on October 29 and gave underwriters a 30-day option to purchase up to 1,406,250 additional shares at the public offering price, less underwriting discounts and commissions.

In its October 22 registration statement, Aspen said there had been no public market for its common stock before the offering. The earlier filing did not establish the final IPO price.

Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank and Oppenheimer & Co. are joint bookrunning managers.

Parkinson’s therapy in development

San Diego-based Aspen is a clinical-stage regenerative medicine company developing therapies derived from patients’ own cells. Its lead candidate, sasineprocel, is an investigational single-dose cell therapy being evaluated for Parkinson’s disease.

Next milestone

The next confirmed milestone is the expected November 2 closing, subject to customary conditions.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.